南宫NG28

Company Updates

Global First: α-Thalassemia Patient Successfully Freed from Blood Transfusion Dependence through Gene Therapy!

On February 10, 2023, Hemogen Theropeutic Co.Ltd (Hemogen, a subsidiary of BGI), Thalassemia Diagnosis and Treatment Innovation Research Center of Nan...

ONE BGI: Hemogen Visits the Middle East and Southeast Asia, Initiating Overseas Implementation of " Creating A Thalassemia-Free World Together "

The Middle East and Southeast Asia are high-prevalence areas for thalassemia and sickle cell anemia as well as significant regions along Belt and Road...

The kick-off meeting of “HGI-002 Injection (Treatment of α-Thalassemia)” was successfully held!

Shenzhen Hemogen Therapeutics Co., Ltd. (hereinafter referred to as: HGI) cooperated with department of hematology of 923 Hospital on the topic of “Cl...

HGI-001 Injection" clinical research (β-thalassemia) kick-off meeting was successfully held!

The kick-off meeting of "HGI-001 Injection" in cooperation with Shenzhen University General Hospital was held successfully on November 15th,...

BGI group gives hope to transfusion-dependent thalassemia (TDT) patients and their families

Dasai and his sister are from a small village in Guangxi Province. They are both diagnosed with transfusion-dependent thalassemia (TDT). Unfortunatel...

Previous 1 2 3 Next

info@thg66.com